cbc.ca/news/canada/ot…

bbc.com/news/health-38…

bbc.com/news/video_and…

GeNeuro Announces Accelerated Timeline for CHANGE-MS Phase IIb Study. lifesci.bluematrix.com/sellside/Email…

bbc.com/news/entertain…

'Scientific quackery': UBC study says it's debunked controversial MS procedure vein-widening 'liberation therapy'. cbc.ca/news/health/mu…

Paralysis inspires MS discovery bbc.com/news/health-39…

Trump's big pharma impact video.cnbc.com/gallery/?video…

cnbc.com/2017/04/13/tra…

bbc.co.uk/newsbeat/artic…

cnbc.com/2017/06/27/gop…

cnbc.com/2017/10/04/myl…

ECTRIMS 2017 - Session on Late-Breaking News in MS lifesci.bluematrix.com/sellside/Email…

ECTRIMS 2017 - Parallel Sessions Days 2-3 lifesci.bluematrix.com/sellside/Email…

ECTRIMS 2017 - Recapping Conference Highlights lifesci.bluematrix.com/sellside/Email…

Celgene Corporation (NASDAQ:CELG) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ozanimod in development for the treatment of patients with relapsing forms of MS.

Ozanimod is a novel, oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator. Upon its preliminary review, the FDA determined that the nonclinical and clinical pharmacology sections in the NDA were insufficient to permit a complete review.

Celgene intends to seek immediate guidance, including requesting a Type A meeting with the FDA, to ascertain what additional information will be required to resubmit the NDA.

We remain confident in ozanimod's clinical profile demonstrated in the pivotal program in relapsing forms of MS," said Jay Backstrom, M.D., Chief Medical Officer and Head of Global Regulatory Affairs for Celgene. We will work with the FDA to address all items.

bbc.co.uk/news/resources…